We discover and drug novel targets once thought beyond reach, unlocking transformative therapies for fibrotic diseases.

Our Approach

Cincera’s discovery platform builds on the pioneering research of Professors Bernard Flynn (Monash Institute of Pharmaceutical Science) and Stuart Pitson (Centre for Cancer Biology). From a series of antifibrotic phenotypic assays, we have identified compounds that act through a unique biological pathway with a first-in-class, orthogonal mechanism of action that interrupts a central node pathway of fibrotic diseases.

Unlike existing antifibrotic therapies, which are constrained by modest efficacy (pathway redundancy) and dose-limiting toxicities, our novel drug-like agents have demonstrated a strong safety profile (chronic tox) and robust single-agent efficacy across key models of kidney, liver, and lung fibrosis. Importantly, our lead drug-like compounds can reduce fibrosis at only 10–20% of the no-adverse-effect level, with efficacy outcomes comparable to or exceeding clinically validated benchmark agents used at their maximum tolerated doses.

We are developing these molecules as pan-antifibrotic therapies — potentially effective across multiple indications, as monotherapy or in rational combinations, independent of disease stage or underlying cause.

Cincera is advancing through late discovery and preclinical development, with preparations underway for CMC and clinical studies in a nominated lead indication.